8 February 2024 - In clinical trials, patients taking Vyalev achieved the primary endpoint of a reduction in motor fluctuations and morning akinesia, as well as improvements in sleep quality and quality of life.

AbbVie today announced that Vyalev (foslevodopa/foscarbidopa solution) is now available for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper/dyskinesia despite optimised treatment with available combinations of Parkinson's medicinal products.

Read AbbVie press release